Vanguard Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $254M | Buy |
11,810,729
+993,283
| +9% | +$20.9M | ﹤0.01% | 1411 |
|
|
2025
Q3 | $208M | Buy |
10,817,446
+1,657,267
| +18% | +$29.5M | ﹤0.01% | 1519 |
|
|
2025
Q2 | $157M | Buy |
9,160,179
+127,566
| +1% | +$5.44M | ﹤0.01% | 1629 |
|
|
2025
Q1 | $576M | Sell |
9,032,613
-52,843
| -0.6% | -$5.56M | 0.01% | 913 |
|
|
2024
Q4 | $1.1B | Buy |
9,085,456
+117,904
| +1% | +$14.4M | 0.02% | 626 |
|
|
2024
Q3 | $1.12B | Sell |
8,967,552
-68,072
| -0.8% | -$9.41M | 0.02% | 627 |
|
|
2024
Q2 | $1.43B | Buy |
9,035,624
+239,870
| +3% | +$30.8M | 0.03% | 534 |
|
|
2024
Q1 | $1.14B | Sell |
8,795,754
-20,370
| -0.2% | -$2.5M | 0.02% | 610 |
|
|
2023
Q4 | $850M | Buy |
8,816,124
+243,180
| +3% | +$23.3M | 0.02% | 680 |
|
|
2023
Q3 | $1.04B | Buy |
8,572,944
+41,465
| +0.5% | +$4.69M | 0.03% | 591 |
|
|
2023
Q2 | $977M | Buy |
8,531,479
+418,515
| +5% | +$54M | 0.02% | 622 |
|
|
2023
Q1 | $1.12B | Buy |
8,112,964
+79,700
| +1% | +$10.3M | 0.03% | 563 |
|
|
2022
Q4 | $1.04B | Sell |
8,033,264
-52,253
| -0.6% | -$6.06M | 0.03% | 565 |
|
|
2022
Q3 | $894M | Sell |
8,085,517
-334,530
| -4% | -$33.7M | 0.03% | 604 |
|
|
2022
Q2 | $631M | Buy |
8,420,047
+104,865
| +1% | +$7.71M | 0.02% | 737 |
|
|
2022
Q1 | $650M | Buy |
8,315,182
+4,074
| +0% | +$312K | 0.02% | 811 |
|
|
2021
Q4 | $748M | Buy |
8,311,108
+830,457
| +11% | +$71M | 0.02% | 776 |
|
|
2021
Q3 | $692M | Buy |
7,480,651
+24,249
| +0.3% | +$1.87M | 0.02% | 796 |
|
|
2021
Q2 | $580M | Buy |
7,456,402
+90,302
| +1% | +$6.85M | 0.01% | 900 |
|
|
2021
Q1 | $549M | Buy |
7,366,100
+148,842
| +2% | +$13.7M | 0.01% | 900 |
|
|
2020
Q4 | $1.23B | Buy |
7,217,258
+126,076
| +2% | +$18.7M | 0.04% | 517 |
|
|
2020
Q3 | $996M | Sell |
7,091,182
-26,515
| -0.4% | -$4.03M | 0.03% | 515 |
|
|
2020
Q2 | $1.14B | Buy |
7,117,697
+572,908
| +9% | +$78M | 0.04% | 460 |
|
|
2020
Q1 | $640M | Buy |
6,544,789
+160,001
| +3% | +$18.3M | 0.03% | 577 |
|
|
2019
Q4 | $824M | Buy |
6,384,788
+19,558
| +0.3% | +$1.97M | 0.03% | 610 |
|
|
2019
Q3 | $479M | Buy |
6,365,230
+132,806
| +2% | +$15.7M | 0.02% | 807 |
|
|
2019
Q2 | $947M | Buy |
6,232,424
+232,752
| +4% | +$28.3M | 0.04% | 531 |
|
|
2019
Q1 | $715M | Buy |
5,999,672
+134,349
| +2% | +$17.3M | 0.03% | 617 |
|
|
2018
Q4 | $640M | Buy |
5,865,323
+480,424
| +9% | +$60.1M | 0.03% | 600 |
|
|
2018
Q3 | $870M | Buy |
5,384,899
+170,999
| +3% | +$23.4M | 0.03% | 564 |
|
|
2018
Q2 | $689M | Buy |
5,213,900
+60,323
| +1% | +$5.69M | 0.03% | 625 |
|
|
2018
Q1 | $382M | Buy |
5,153,577
+72,519
| +1% | +$4.84M | 0.02% | 888 |
|
|
2017
Q4 | $283M | Buy |
5,081,058
+145,275
| +3% | +$7.7M | 0.01% | 1064 |
|
|
2017
Q3 | $224M | Buy |
4,935,783
+676,754
| +16% | +$27M | 0.01% | 1191 |
|
|
2017
Q2 | $144M | Buy |
4,259,029
+162,543
| +4% | +$5.29M | 0.01% | 1462 |
|
|
2017
Q1 | $121M | Buy |
4,096,486
+176,966
| +5% | +$5.48M | 0.01% | 1548 |
|
|
2016
Q4 | $108M | Buy |
3,919,520
+239,175
| +6% | +$9.61M | 0.01% | 1573 |
|
|
2016
Q3 | $226M | Buy |
3,680,345
+574,529
| +18% | +$17.4M | 0.01% | 1034 |
|
|
2016
Q2 | $59.2M | Buy |
3,105,816
+161,790
| +5% | +$3M | ﹤0.01% | 1822 |
|
|
2016
Q1 | $57.5M | Buy |
2,944,026
+103,897
| +4% | +$1.82M | ﹤0.01% | 1803 |
|
|
2015
Q4 | $110M | Buy |
2,840,129
+268,538
| +10% | +$8.71M | 0.01% | 1401 |
|
|
2015
Q3 | $82.6M | Buy |
2,571,591
+69,418
| +3% | +$2.36M | 0.01% | 1571 |
|
|
2015
Q2 | $76.1M | Buy |
2,502,173
+78,763
| +3% | +$1.61M | 0.01% | 1710 |
|
|
2015
Q1 | $32.2M | Buy |
2,423,410
+132,696
| +6% | +$1.77M | ﹤0.01% | 2129 |
|
|
2014
Q4 | $33.1M | Buy |
2,290,714
+82,961
| +4% | +$1.4M | ﹤0.01% | 2025 |
|
|
2014
Q3 | $46.6M | Sell |
2,207,753
-22,198
| -1% | -$501K | ﹤0.01% | 1834 |
|
|
2014
Q2 | $66.4M | Buy |
2,229,951
+126,020
| +6% | +$3.98M | 0.01% | 1678 |
|
|
2014
Q1 | $50.6M | Buy |
2,103,931
+42,593
| +2% | +$1.09M | ﹤0.01% | 1800 |
|
|
2013
Q4 | $42M | Buy |
2,061,338
+326,375
| +19% | +$9.7M | ﹤0.01% | 1872 |
|
|
2013
Q3 | $81.9M | Buy |
1,734,963
+127,967
| +8% | +$4.93M | 0.01% | 1380 |
|
|
2013
Q2 | $61.1M | Buy |
+1,606,996
| New | +$57.5M | 0.01% | 1493 |
|
Other funds holding SRPT
EAM
Vanguard Group's SRPT Position: Q4 2025 in Review
Vanguard Group increased its Sarepta Therapeutics (SRPT) stake by 9.2% in Q4 2025, buying an estimated $20.9M and bringing the position to 11,810,729 shares worth $254M. The position accounts for ﹤0.01% of the portfolio, ranked #1411.
Vanguard Group first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.43B in Q2 2024. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.
- Vanguard Group held 11,810,729 shares of Sarepta Therapeutics worth $254M as of Q4 2025.
- Vanguard Group bought 993,283 Sarepta Therapeutics shares in Q4 2025, an estimated $20.9M.
- Sarepta Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1411 holding.
- Vanguard Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Sarepta Therapeutics position peaked at $1.43B in Q2 2024.
- 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.